ASH 2023 | The impact of the spectrum of ASXL1 mutations on disease outcomes in MF
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on a study which investigated the impact the presence of ASXL1 mutation variants had on disease outcomes in patients with primary myelofibrosis or post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF) at the time of hematopoietic stem cell transplantation (HSCT). ASXL1 mutations were associated with poorer outcomes in these patients post-HSCT (as has been previously documented), however no variants of the mutation had a higher association with poor prognosis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
